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with breast cancer in the UK NHS. METHODS: A previously published decision tree
model was populated and developed with the Vial et. al. and Brown et. al. trial data
to assess the cost-effectiveness of using branded Taxotere®versus its generic coun-
terpart docetaxel from the UK NHS perspective. RESULTS: If the branded Taxotere®
was promoted as the first-line therapy, it would cost the UK NHS £411.54 per vial
per patient with 0.434 QALY (Quality-Adjusted Life Years) gain compared to £412.98
with 0.418 QALY gain if the generic docetaxel was promoted instead and failed the
therapy. Although the acquisition cost of docetaxel is more than 50% less than that
of Taxotere®, promoting the generic docetaxel based on its lower acquisition cost,
only, would result in increasing the total health care cost compared to Taxotere®.
CONCLUSIONS: Based on the decision tree model generated in this study, promot-
ing the branded Taxotere® is more cost-effective compared to its generic counter-
part docetaxel. This should be considered for implementation in practice and for
future guidelines.
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OBJECTIVES: To estimate which is the dominant treatment between the only two
drugs that had been able to demonstrate overall survival (OS) improvements in
patients with metastatic castrate resistant prostate cancer (mCRPC) that have pro-
gressed on or after docetaxel treatment, and that were approved by the EMA in 2011
(AA by accelerated procedure): cabazitaxel (CBZ) and abiraterone acetate (AA),.
METHODS: We replicated the methodology most commonly used by Spanish hos-
pitals to estimate the cost-efficacy of oncologic drugs (OS gains and incremental
costs vs. those of comparators) by: (i) taking the perspective of the Spanish NHS (ii)
estimating treatment costs based on the product labels (i.e. main medication, co-
medication, premedication, and primary prophylaxis) at ex-factory prices, and the
cost of administering such medications; and (iii) the OS data from the respective
pivotal phase III trials: for CBZ vs. mitoxantrone prednisone (MP) OS was 15.1 vs.
12.7 months. For AA vs. placebo prednisone (PP) OS was 15.8 vs. 11.2. Input for the
base case analysis comes from Phase III randomized clinical trials and from pub-
licly available cost data. Sensitivity analysis was performed on: (i) length of treat-
ment; (ii) median OS; and (iii) G-CSF usage and drug administration costs.
RESULTS: In our base case scenario the cost per cycle of CBZ was 4,711.52€ vs.
78.20€ for MP. The cost per cycle of AA was 3,179.26€ vs. 11.85€ for PP. Treatment
costs difference for CBZ vs. MP is 27,799.93€ (range 13,665.36€ – 46,646.01€) and for
AA vs. PP is 25,386.71€ (range 12,669.65€ - 38,103.76€). OS gain is 2.4 months for CBZ
and 4.6 months for AA. CONCLUSIONS: In Spain, based on local hospital method-
ology, AA would be the dominant alternative (higher OS gain and lower incremen-
tal cost) to treat mCRPC patients that have progressed on or after a docetaxel based
regime.
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OBJECTIVES: In Germany, health economic studies are increasingly based on
health insurance claims data analysis. Such data offer a wide range of scientific
applications, especially when focusing on the assessment of resource utilization
patterns and costs. The objective of our study was to estimate the direct health care
costs of three frequent types of cancer (colorectal, breast, and prostate cancer) from
a third-party payer perspective using longitudinal data from a German statutory
health insurance fund and employing a matched pairs design. METHODS: Our
analysis is based on administrative data of a German sickness fund covering a
5-year period (2005-2009). A total of 42,085 cancer patients were included. Disease-
specific costs were estimated by matching cancer patients to counterparts without
the particular condition and subsequently comparing the costs of the two groups.
One-to-one matching was performed by application of the propensity score
method to balance patient characteristics among the cancer groups and non-can-
cer controls. The cost categories considered in this study included prescription
drug costs, outpatient visit costs, and hospitalization costs. RESULTS: The mean
cancer-associated 5-year costs per patient amounted to €5,429 for colorectal can-
cer, €3,200 for breast cancer, and €5,350 for prostate cancer. The average disease-
attributable costs of the first year following diagnosis were €8,750, €4,300, and
€4,750 for colorectal, breast and prostate cancer, respectively. Corresponding ex-
cess costs of the last year of life were €15,900, €10,950, and €14,750. Costs associated
with hospitalization accounted for a major part of the total disease-specific costs
(up to 80%). CONCLUSIONS: This cost-of-illness study based on claims data anal-
ysis confirms the high economic burden of colorectal, breast, and prostate cancer.
Most of the costs occurred in the initial and terminal treatment phases. Inpatient
treatment was found to be the main cost driver.
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Incidence of penile cancer in Europe is slightly increasing. Survival rates in penile
cancer are good, however, there is little research into treatment costs.OBJECTIVES:
To estimate the cost of treating penile cancer in English hospitals, using data from
the HES database. This investigation is part of a wider project aimed at quantifying
the total economic burden of penile cancer in the UK. METHODS: Inpatient admis-
sions for penile cancer between the years 2006/07 to 2010/11 were retrospectively
analysed. Data was obtained from HES, a database covering English hospital activ-
ity, with inpatient episodes aggregated into spells of care associated with a specific
Healthcare Resource Group (HRG). The HRGs were linked to costs from the UK
National Tariff in order to calculate the average annual and per patient payments
for inpatient treatment of penile cancer, as per the NHS Payment by Results frame-
work. Where necessary, costs were supplemented by expert opinion and other
published cost estimates. A limited amount of HES data on outpatient consulta-
tions was also collected and analysed. RESULTS: The mean annual amount paid to
English hospitals for inpatient treatment of invasive penile cancer in England was
estimated to be £2,391,700, with a further £189,106 paid for carcinoma in situ of the
penis. Per inpatient, mean costs were approximately £3,743 and £1,323 for invasive
penile cancer and carcinoma in situ, respectively. Outpatient costs were consider-
ably lower, due to the majority of care being delivered in an inpatient setting and
issues with HES outpatient data collection. Further research into outpatient costs is
currently ongoing. CONCLUSIONS: The burden of penile cancer in the UK has cost
implications, the full extent of which cannot yet be ascertained due to underesti-
mation of outpatient costs. Any preventive intervention aimed at decreasing this
burden should be carefully considered.
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OBJECTIVES: To estimate the costs associated with melanoma for Russia in 2009.
METHODS: Prevalence-based cost-of-illness analysis (COI) was performed from
the payer’s point of view (national and regional governments). Direct medical costs
(hospital and outpatient services and drugs provided in outpatient care), non-med-
ical costs (monetary payments in social benefits) and indirect costs (projected pro-
ductivity loss due to sickness and disability) associated with melanoma in Russia in
2009 were calculated. We obtained the data for analysis from the national statis-
tics, regional cancer and prescription registries, expert panel interviews and liter-
ature. The costs were calculated for the total population of melanoma patients in
Russia. To calculate direct medical costs, we used national reimbursement rates
per unit of care (1 hospital day or 1 visit to an out-patient oncology clinic) and
regional data on melanoma drug costs. To access non-medical costs, we used data
on social benefits expenditures. Indirect costs were estimated with friction costs
method. RESULTS: The total costs of melanoma in Russia in 2009 was 771,2 million
RUR (€18,8mln), or 11 314 RUR (€275,9) as average cost per patient per year. Almost
half of total costs (48.3%) occur in patients during the 1st year after diagnosis. The
direct medical costs accounted for 52,41% of total spending, direct non-medical
costs – for 34,9%, and indirect costs – for 12,69%. Direct medical costs represented
72,8% of total spending in melanoma patients within the 1st year after the diagno-
sis; during the subsequent years after the diagnosis this number reduces to 34,2%.
CONCLUSIONS: Our analysis demonstrates that the most significant part of med-
ical costs for melanoma occur during the 1st year after diagnosis that corresponds
with the results of other COI studies in oncology; in subsequent years the main
costs are outside the scope of health care system.
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OBJECTIVES:Despite the considerable disease burden of ovarian cancer (OC), there were
no cost studies in Central and Eastern Europe. This study aimed to describe treatment
patterns, health care resource utilization and costs associated with OC in Hungary, Po-
land, Serbia and Slovakia. METHODS: Overall clinical practice for management of
epithelial ovarian cancer was investigated through a three-round Delphi panel
consisting of 15 clinical experts. Experts completed a survey based on patient re-
cords (N1,542). The survey was developed based on clinical guidelines and the
FIGO Annual Report. Means, ranges and outlier values were discussed with the
experts during a telephone interview. Finally, consensus estimates were obtained
in face-to-face workshops. Based on these results, overall cost of OC was estimated
using a Markov model. RESULTS: The patients included in the chart review were
followed from pre-surgical diagnosis and in each phase of treatment, i.e. primary
surgical staging and surgery, chemotherapy and chemotherapy monitoring, fol-
low-up and palliative care. Overall treatment patterns were similar but regimens in
second and subsequent lines of chemotherapy varied across the countries. The
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